car-t
No description yet: the sentence for this tag has not been written. 13 records carry it: 13 people.
Related tags
13 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Caron A. Jacobson Lymphoma specialist and medical director of immune effector cell therapy, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma. | Follicular lymphoma, Marginal zone lymphoma, Non-Hodgkin lymphoma | none | lymphoma, cell-therapy, trialist | ||
Jason R. Westin Director of Lymphoma Clinical Research, MD Anderson Cancer Center · MD Anderson Cancer Center Led the ZUMA-7 overall survival analysis that made CAR-T the standard second-line therapy for early-relapsing lymphoma. | Diffuse large B-cell lymphoma | none | lymphoma, second-line | ||
Jesús G. Berdeja Director of Myeloma Research, Greco-Hainsworth Centers for Research, Tennessee Oncology; Sarah Cannon Research Institute · Tennessee Oncology / Greco-Hainsworth Centers for Research Led CARTITUDE-1, the trial that brought ciltacabtagene autoleucel, the most active myeloma CAR-T, to approval. | Multiple myeloma | none | myeloma, community-research | ||
Marcela V. Maus Director, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center; Professor, Harvard Medical School · Massachusetts General Hospital Cancer Center Cell therapy engineer whose CAR-TEAM cells produced rapid regressions of recurrent glioblastoma. | Glioma & glioblastoma | none | cell-therapy, solid-tumours | ||
Michael L. Wang Puddin Clarke Endowed Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center · MD Anderson Cancer Center Led the ibrutinib and brexucabtagene autoleucel trials that transformed mantle cell lymphoma treatment. | Mantle cell lymphoma | none | lymphoma, mantle-cell | ||
Michel Sadelain Director, Columbia Initiative in Cell Engineering and Therapy, Columbia University Irving Medical Center · Herbert Irving Comprehensive Cancer Center, Columbia University Designed the second-generation CAR with a CD28 costimulatory domain that made CAR-T therapy work. | Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma | none | cell-therapy, engineering | ||
Michelle Monje Professor of Neurology and Neurological Sciences, Stanford University; HHMI Investigator · Stanford Health Care / Stanford Cancer Institute Founded cancer neuroscience and led the GD2 CAR-T trial that produced the first regressions of diffuse midline glioma. | none | none | paediatric, glioma, cancer-neuroscience | ||
Nikhil C. Munshi Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Led KarMMa, which brought idecabtagene vicleucel, the first CAR-T for myeloma, to approval. | Multiple myeloma | none | myeloma, genomics | ||
Noopur Raje Director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center · Massachusetts General Hospital Cancer Center Led the first-in-human trial of BCMA CAR-T (bb2121) in myeloma and studies of bone disease treatment. | Multiple myeloma | none | myeloma, bone-disease | ||
Robbie G. Majzner Director of Solid Tumor Immunotherapy, Department of Oncology, St. Jude Children's Research Hospital · St. Jude Children's Research Hospital Led the GD2 CAR-T trial in diffuse midline glioma and defined antigen density as a barrier to CAR-T in solid tumours. | Neuroblastoma, Osteosarcoma | none | cell-therapy, paediatric | ||
Sattva S. Neelapu Professor and Deputy Chair, Department of Lymphoma and Myeloma, MD Anderson Cancer Center · MD Anderson Cancer Center Led ZUMA-1, the trial that made axicabtagene ciloleucel the first CAR-T therapy approved for lymphoma. | Diffuse large B-cell lymphoma, Follicular lymphoma | none | lymphoma, cell-therapy | ||
Stephan A. Grupp Chief, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia; Professor of Pediatrics, University of Pennsylvania · Children's Hospital of Philadelphia Treated the first child with CAR-T cells and led ELIANA, the trial behind the first CAR-T approval. | Acute lymphoblastic leukaemia | none | cell-therapy, paediatric | ||
Stephen J. Schuster Robert and Margarita Louis-Dreyfus Professor in CLL and Lymphoma, Abramson Cancer Center, University of Pennsylvania · Abramson Cancer Center, University of Pennsylvania Led JULIET, which brought tisagenlecleucel, the first CAR-T, to adults with relapsed large B-cell lymphoma. | Diffuse large B-cell lymphoma, Follicular lymphoma | none | lymphoma, cell-therapy |
